In8bio Inc Stock Analysis
| INAB Stock | USD 1.99 0.09 4.74% |
IPO Date 30th of July 2021 | 200 Day MA 2.5096 | 50 Day MA 2.0124 | Beta (0.01) |
In8bio Inc holds a debt-to-equity ratio of 0.075. At present, In8bio's Debt To Equity is projected to increase slightly based on the last few years of reporting. The current year's Interest Debt Per Share is expected to grow to 0.09, whereas Net Debt is forecasted to decline to (5.8 M). With a high degree of financial leverage come high-interest payments, which usually reduce In8bio's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
In8bio's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. In8bio's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps In8bio Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect In8bio's stakeholders.
For many companies, including In8bio, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for In8bio Inc, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, In8bio's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
At present, In8bio's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Common Stock Shares Outstanding is expected to grow to about 64.7 M, whereas Common Stock Total Equity is forecasted to decline to 800.00. . At present, In8bio's Price Book Value Ratio is projected to decrease significantly based on the last few years of reporting. The current year's Price Earnings To Growth Ratio is expected to grow to 0.30, whereas Price Earnings Ratio is forecasted to decline to (12.83). In8bio Inc is undervalued with Real Value of 4.47 and Target Price of 12.5. The main objective of In8bio stock analysis is to determine its intrinsic value, which is an estimate of what In8bio Inc is worth, separate from its market price. There are two main types of In8bio's stock analysis: fundamental analysis and technical analysis.
The In8bio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and In8bio's ongoing operational relationships across important fundamental and technical indicators.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in In8bio Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. In8bio Stock Analysis Notes
About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.5. Some equities with similar Price to Book (P/B) outperform the market in the long run. In8bio Inc recorded a loss per share of 5.26. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 6th of June 2025. IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. In8Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. To learn more about In8bio Inc call the company at 646 600 6438 or check out https://in8bio.com.In8bio Inc Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. In8bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding In8bio Inc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| In8bio Inc had very high historical volatility over the last 90 days | |
| In8bio Inc may become a speculative penny stock | |
| In8bio Inc has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (30.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| In8bio Inc currently holds about 25.74 M in cash with (24.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.37. | |
| In8bio Inc has a frail financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: IN8bio to Present at Upcoming Investor and Scientific Conferences in February |
In8bio Largest EPS Surprises
Earnings surprises can significantly impact In8bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-13 | 2024-12-31 | -0.07 | -0.08 | -0.01 | 14 | ||
2024-11-12 | 2024-09-30 | -0.17 | -0.15 | 0.02 | 11 | ||
2024-08-09 | 2024-06-30 | -0.17 | -0.19 | -0.02 | 11 |
In8bio Stock Institutional Investors
| Shares | Bank Of America Corp | 2025-06-30 | 24.0 | Goldman Sachs Group Inc | 2025-03-31 | 0.0 | 683 Capital Management Llc | 2025-03-31 | 0.0 | State Street Corp | 2025-06-30 | 0.0 | Susquehanna International Group, Llp | 2025-06-30 | 0.0 | Jane Street Group Llc | 2025-03-31 | 0.0 | Northern Trust Corp | 2025-06-30 | 0.0 | Sigma Planning Corp | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 0.0 | Bios Capital Management, Lp | 2025-03-31 | 8.6 M | Franklin Resources Inc | 2025-06-30 | 189.9 K |
In8bio Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.43 M.In8bio Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.31) | (1.37) | |
| Return On Capital Employed | (1.53) | (1.61) | |
| Return On Assets | (1.31) | (1.37) | |
| Return On Equity | (2.42) | (2.30) |
Management Efficiency
In8bio Inc has return on total asset (ROA) of (0.8039) % which means that it has lost $0.8039 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8972) %, meaning that it created substantial loss on money invested by shareholders. In8bio's management efficiency ratios could be used to measure how well In8bio manages its routine affairs as well as how well it operates its assets and liabilities. As of February 7, 2026, Return On Tangible Assets is expected to decline to -1.37. In addition to that, Return On Capital Employed is expected to decline to -1.61. At present, In8bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 46.1 M, whereas Non Current Assets Total are forecasted to decline to about 5.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.24 | 0.23 | |
| Tangible Book Value Per Share | 0.24 | 0.23 | |
| Enterprise Value Over EBITDA | (13.60) | (14.28) | |
| Price Book Value Ratio | 25.70 | 26.98 | |
| Enterprise Value Multiple | (13.60) | (14.28) | |
| Price Fair Value | 25.70 | 26.98 | |
| Enterprise Value | 468.4 M | 445 M |
Evaluating the management effectiveness of In8bio allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The In8bio Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
As of the 7th of February, In8bio owns the Market Risk Adjusted Performance of 0.1673, semi deviation of 5.08, and Standard Deviation of 7.13. In8bio Inc technical analysis makes it possible for you to employ past data patterns with the intention to determine a pattern that calculates the direction of the firm's future prices.In8bio Inc Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in In8bio price series with the more recent values given greater weights.
In8bio Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific In8bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on In8bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases In8bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
In8bio Outstanding Bonds
In8bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. In8bio Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most In8bio bonds can be classified according to their maturity, which is the date when In8bio Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
In8bio Predictive Daily Indicators
In8bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of In8bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
In8bio Forecast Models
In8bio's time-series forecasting models are one of many In8bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary In8bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.In8bio Bond Ratings
In8bio Inc financial ratings play a critical role in determining how much In8bio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for In8bio's borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (5.62) | Unlikely Manipulator | View |
In8bio Inc Debt to Cash Allocation
As In8bio Inc follows its natural business cycle, the capital allocation decisions will not magically go away. In8bio's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
In8bio Inc currently holds 5.03 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. In8bio Inc has a current ratio of 8.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about In8bio's use of debt, we should always consider it together with its cash and equity.In8bio Total Assets Over Time
In8bio Assets Financed by Debt
The debt-to-assets ratio shows the degree to which In8bio uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.In8bio Debt Ratio | 23.0 |
In8bio Corporate Bonds Issued
Most In8bio bonds can be classified according to their maturity, which is the date when In8bio Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
In8bio Net Debt
Net Debt |
|
About In8bio Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how In8bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling In8bio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as In8bio. By using and applying In8bio Stock analysis, traders can create a robust methodology for identifying In8bio entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current In8bio Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. In8bio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. In8bio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 12.5 | Strong Buy | 4 | Odds |
Most In8bio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand In8bio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of In8bio Inc, talking to its executives and customers, or listening to In8bio conference calls.
In8bio Stock Analysis Indicators
In8bio Inc stock analysis indicators help investors evaluate how In8bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading In8bio shares will generate the highest return on investment. By understating and applying In8bio stock analysis, traders can identify In8bio position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 21.5 M | |
| Common Stock Shares Outstanding | 53.5 M | |
| Total Stockholder Equity | 14.5 M | |
| Total Cashflows From Investing Activities | -187 K | |
| Property Plant And Equipment Net | 7.8 M | |
| Cash And Short Term Investments | 11.1 M | |
| Cash | 11.1 M | |
| Accounts Payable | 389 K | |
| Net Debt | -6.1 M | |
| 50 Day M A | 2.0124 | |
| Total Current Liabilities | 3.1 M | |
| Other Operating Expenses | 30.4 M | |
| Non Current Assets Total | 8.4 M | |
| Non Currrent Assets Other | 275 K | |
| Stock Based Compensation | 5 M |
Complementary Tools for In8bio Stock analysis
When running In8bio's price analysis, check to measure In8bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In8bio is operating at the current time. Most of In8bio's value examination focuses on studying past and present price action to predict the probability of In8bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In8bio's price. Additionally, you may evaluate how the addition of In8bio to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |